Table 1.
Baseline characteristics
| Variable | Medical treatment (n=30) | EVT (n=51) | p-value |
|---|---|---|---|
| Age | 68(61.75–78.25) | 73 (64–78) | 0.252* |
| Female | 8 (26.7) | 22 (43.1) | 0.138 |
| Intravenous rtPA use | 9 (30.0) | 20 (39.2) | 0.403 |
| Baseline NIHSS | 13 (9–17.25) | 16 (11–20) | 0.074* |
| Onset to door time | 231.5 (89–382) | 268(113–693.5) | 0.315* |
| ASPECTS DWI | 9 (8–10) | 9 (8–10) | 0.700* |
| Medical history | |||
| Hypertension | 21 (70.0) | 33 (64.7) | 0.625 |
| Diabetes | 12 (40.0) | 18 (35.3) | 0.672 |
| Hyperlipidemia | 18 (60.0) | 18 (35.3) | 0.031 |
| Atrial fibrillation | 9 (30.0) | 22 (43.1) | 0.24 |
| Coronary disease | 6 (20.0) | 8 (15.7) | 0.62 |
| Current smoking | 11 (36.7) | 20 (39.2) | 0.82 |
| Previous Stroke | 5 (16.7) | 9 (17.6) | 0.91 |
| Antiplatelet use | 9 (30.0) | 22 (43.1) | 0.24 |
| Anticoagulant use | 3 (10.0) | 2 (3.9) | 0.354* |
| Occlusion location | 0.005 | ||
| Extracranial ICA | 20 (66.7) | 15 (29.4) | |
| Intracranial ICA | 8 (26.7) | 27 (52.9) | |
| ICA and tandem MCA branches | 2 (6.7) | 9 (17.6) | |
| Route of collaterals | 0.676 | ||
| Anterior communicating artery | 15 (50.0) | 22 (43.1) | |
| Posterior communicating artery | 8 (26.7) | 12 (23.5) | |
| Anterior & posterior communicating artery | 2 (6.7) | 8 (15.7) | |
| Ophthalmic artery | 5 (16.7) | 9 (17.6) | |
| Delay of contrast filling time for MCA territory (seconds) | 1.5 (1.0–2.1) | 3.0 (2.2–4.0) | <0.001 |
| Stroke subtypes | 0.024 | ||
| Large artery atherosclerosis | 21 (70.0) | 21 (41.2) | |
| Cardioembolism | 5 (16.7) | 23 (45.1) | |
| Undetermined | 4 (13.3) | 7 (13.7) |
Values are presented as median (interquartile range) or number (%).
*
Mann whitney U test.
EVT : endovascular treatment, rtPA : recombinant tissue plasminogen activator, NIHSS : National Institute of Health Stroke Scale, ASPECTS : Alberta Stroke Program Early CT Score, DWI : diffusionweighted imaging, ICA : internal carotid artery, MCA : middle cerebral artery